{"anticipatedPostingDate":"2027-04","denomUnitsSelected":"Participants","description":"TEAEs were events with onset after the administration of the first dose of any trial treatment up to EOT or 30 days of the last dose of any trial treatment, or prior to first dose of crossed over treatment, whichever occurred earlier. Clinically significant changes in vital signs, and clinical laboratory tests were included as TEAEs.","reportingStatus":"NOT_POSTED","timeFrame":"Approximately 3 years","title":"Number of Participants With Treatment-emergent Adverse Events (TEAEs)","type":"SECONDARY"}